Chen Kuangyang, Chen Lijiao, Dai Jiarong, Ye Hongying
Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Int J Endocrinol. 2023 Apr 12;2023:6637396. doi: 10.1155/2023/6637396. eCollection 2023.
This study aims to analyze the clinical characteristic of metabolic associated fatty liver disease (MAFLD) in patients with active Cushing's disease (CD) and determine associations of thyroid hormones with MAFLD.
Patients with active CD were included in this cross-sectional study. All subjects were assessed for hepatic steatosis by abdominal ultrasonography and thyroid functions. Demographic and clinical characteristic parameters were collected for correlation analysis and logistic analysis.
290 individuals with active CD were included in Huashan hospital from January 2014 to February 2022. We found that the prevalence of CD with MAFLD was 33.79%. The MAFLD group had a lower level of FT4 and a higher level of FT3/FT4 but no difference in levels of cortisol, 24 h UFC, TSH, TT4, TT3, and FT3. Correlation analysis showed positive associations of TSH, TT4, TT3, FT3, and FT3/FT4 with BMI. In age-, BMI-, sex-, cortisol-, and 24 h UFC-adjusted analysis, FT4 was independently associated with MAFLD in patients with CD. This association remained similar even after adjusting for the presence of metabolic syndrome components.
Lower FT4 levels were associated with higher risk of MAFLD in patients with CD. FT4 may be used as a helpful indicator to predict MAFLD and provide novel ideas for the treatment of MAFLD in patients with CD in the future.
本研究旨在分析活动性库欣病(CD)患者代谢相关脂肪性肝病(MAFLD)的临床特征,并确定甲状腺激素与MAFLD的关联。
本横断面研究纳入了活动性CD患者。所有受试者均通过腹部超声和甲状腺功能评估肝脂肪变性情况。收集人口统计学和临床特征参数进行相关性分析和逻辑分析。
2014年1月至2022年2月,华山医院共纳入290例活动性CD患者。我们发现,合并MAFLD的CD患病率为33.79%。MAFLD组的游离甲状腺素(FT4)水平较低,游离三碘甲状腺原氨酸/游离甲状腺素(FT3/FT4)水平较高,但皮质醇、24小时尿游离皮质醇(UFC)、促甲状腺激素(TSH)、总甲状腺素(TT4)、总三碘甲状腺原氨酸(TT3)和游离三碘甲状腺原氨酸(FT3)水平无差异。相关性分析显示,TSH、TT4、TT3、FT3和FT3/FT4与体重指数(BMI)呈正相关。在年龄、BMI、性别、皮质醇和24小时UFC校正分析中,FT4与CD患者的MAFLD独立相关。即使在调整代谢综合征组分的存在后,这种关联仍然相似。
CD患者中较低的FT4水平与MAFLD的较高风险相关。FT4可作为预测MAFLD的有用指标,并为未来CD患者MAFLD的治疗提供新思路。